Approaches to Improving Care in Chronic Lymphocytic Leukemia Patients Within the Department of Veterans Affairs: Insights from the Experts
PROGRAM CHAIR
Lori Leslie, MD
Associate Professor of Medicine
Hackensack Meridian Health School of Medicine
Director of CLL and Indolent Lymphoma
John Theurer Cancer Center
Hackensack, NJ
PROGRAM OVERVIEW
In this activity we will discuss the relevance of specific genetic and molecular markers in Chronic Lymphocytic Leukemia (CLL), review the current evidence concerning the application of minimal residual disease (MRD) monitoring, and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings. Finally, we will examine the potential adverse events associated with CLL therapeutics, including specific considerations with combination therapies.
TARGET AUDIENCE
This educational activity is intended for community hematologists, oncologists, and clinicians involved in the assessment, monitoring, and treatment of CLL for patients within the Department of Veteran Affairs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the relevance of specific genetic and molecular markers in CLL for patients within the Department of Veterans Affairs
- Summarize current evidence concerning the application of MRD monitoring in CLL for patients within the Department of Veterans Affairs
- Assess current and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings for patients within the Department of Veterans Affairs
- Explain potential adverse events associated with CLL therapeutics and considerations with specific combinations for patients within the Department of Veterans Affairs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationships
| Speaker | Relationships | Manufacturer |
| Lori A Leslie, MD | Consultant | ADC Therapeutics, Kite Gilead, BeiGene, Pharmacyclics Inc, Merck Pharmacy, Abbvie, Genmab, SeaGen, Janssen, AstraZeneca, and Eli Lily |
| Speakers Bureau | Kite Gilead, Pharmacyclics, Abbvie, Genmab, SeaGen, Janssen, Eli Lily, Epizyme, TG Therapeutics, BeiGene, and AstraZeneca |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, Medical Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
